Tumor-Stroma Proportion to Predict Chemoresistance in Patients With Ovarian Cancer.

ABSTRACT:

Importance

Platinum-based chemotherapy is the backbone of standard-of-care treatment for patients with advanced-stage, high-grade serous carcinoma (HGSC), the most common form of ovarian cancer; however, one-third of patients have or acquire chemoresistance toward platinum-based therapies.

Objective

To demonstrate the utility of tumor-stroma proportion (TSP) as a predictive biomarker of chemoresistance of HGSC, progression-free survival (PFS), and overall survival (OS).

Design, setting, and participants

This prognostic study leveraged tumors from patients with HGSC in The Cancer Genome Atlas (TCGA) cohort (1993-2013) and an independent cohort of resected clinical specimens from patients with HGSC (2004-2014) available in diagnostic and tissue microarray formats from t

SUBMITTER: Lou E 

PROVIDER: S-EPMC10900967 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature